Clinical Trials Browser

Phase 1/2 × Terminated × pirtobrutinib × Clear all

NCT05317936 2025-12-15

Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax

Phase 1/2 Terminated

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell